tbuckley/cabot-search huggingface dataset:
The construction of a lymphoma cell-based, DC-targeted vaccine, and its application in lymphoma prevention and cure
Authors: Tianlin Zhou, Jinrong Peng, Ying Hao, Kun Shi, Kai Zhou, Yun Yang, Chengli Yang, Xinlong He, Xinmian Chen, Zhiyong Qian
Journal: Bioactive Materials (2020)

In recent years, Non-Hodgkin lymphoma (NHL) has been one of the most fast-growing malignant tumor diseases. NHL poses severe damages to physical health and a heavy burden to patients. Traditional therapies (chemotherapy or radiotherapy) bring some benefit to patients, but have severe adverse effects and do not prevent relapse. The relevance of emerging immunotherapy options (immune-checkpoint blockers or adoptive cellular methods) for NHL remains uncertain, and more intensive evaluations are needed. In this work, inspired by the idea of vaccination to promote an immune response to destroy tumors, we used a biomaterial-based strategy to improve a tumor cell-based vaccine and constructed a novel vaccine named Man-EG7/CH@CpG with antitumor properties. In this vaccine, natural tumor cells are used as a vector to load CpG-ODN, and following lethal irradiation, the formulations were decorated with mannose. The study of the characterization of the double-improved vaccine evidenced the enhanced ability of DCs targeting and improved immunocompetence, which displayed an antitumor function. In the lymphoma prevention model, the Man-EG7/CH@CpG vaccine restrained tumor formation with high efficiency. Furthermore, unlike the non-improved vaccine, the double-improved vaccine elicited an enhanced antitumor effect in the lymphoma treatment model. Next, to improve the moderate therapeutic effect of the mono-treatment method, we incorporated a chemotherapeutic drug (doxorubicin, DOX) into the process of vaccination and devised a combination regimen. Fortunately, a tumor inhibition rate of ~85% was achieved via the combination therapy, which could not be achieved by mono-chemotherapy or mono-immunotherapy. In summary, the strategy presented here may provide a novel direction in the establishment of a tumor vaccine and is the basis for a prioritization scheme of immuno-chemotherapy in enhancing the therapeutic effect on NHL.
Incomplete endoscopic resection of colorectal polyps: a prospective quality assurance study
Authors: Ina B. Pedersen, Michael Bretthauer, Mette Kalager, Magnus Løberg, Geir Hoff, Senaria Matapour, Silje Hugin, Svein O. Frigstad, Birgitte Seip, Britta A. Kleist, Leif Løvdal, Edoardo Botteri, Øyvind Holme
Journal: Endoscopy (2020)

Background Endoscopic screening with polypectomy has been shown to reduce colorectal cancer incidence in randomized trials. Incomplete polyp removal and subsequent development of post-colonoscopy cancers may attenuate the effect of screening. This study aimed to quantify the extent of incomplete polyp removal. Methods We included patients aged 50–75 years with nonpedunculated polyps ≥ 5 mm removed during colonoscopy at four hospitals in Norway. To evaluate completeness of polyp removal, biopsies from the resection margins were obtained after polypectomy. Logistic regression models were fitted to identify factors explaining incomplete resection. Results 246 patients with 339 polyps underwent polypectomy between January 2015 and June 2017. A total of 12 polyps were excluded due to biopsy electrocautery damage, and 327 polyps in 246 patients (mean age 67 years [range 42–83]; 52 % male) were included in the analysis. Overall, 54 polyps (15.9 %) in 54 patients were incompletely resected. Histological diagnosis of the polyp (sessile serrated lesions vs. adenoma, odds ratio [OR] 10.9, 95 % confidence interval [CI] 3.9–30.1) and polyp location (proximal vs. distal colon, OR 2.8, 95 %CI 1.0–7.7) were independent risk factors for incomplete removal of polyps 5–19 mm. Board-certified endoscopists were not associated with lower rates of incomplete resection compared with trainees (14.0 % vs. 14.2 %), OR 1.0 (95 %CI 0.5–2.1). Conclusion Incomplete polyp resection was frequent after polypectomy in routine clinical practice. Serrated histology and proximal location were independent risk factors for incomplete resection. The performance of board-certified gastroenterologists was not superior to that of trainees.
A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis
Authors: Yannick Allanore, Peter Wung, Christina Soubrane, Corinne Esperet, Frederic Marrache, Raphael Bejuit, Amel Lahmar, Dinesh Khanna, Christopher P Denton
Journal: Annals of the Rheumatic Diseases (2020)

Objectives Recent advances in systemic sclerosis (SSc) show that it involves a T-helper type-2-oriented immune response with interleukin (IL)-4 and IL-13. Romilkimab is an engineered, humanised, bispecific immunoglobulin-G4 antibody that binds and neutralises IL-4/IL-13 making it ideal for exploration in fibrosis. Methods Patients aged ≥18 years diagnosed with diffuse cutaneous SSc (dcSSc), and with or without immunosuppressive background therapy, were randomised (1:1) to subcutaneous romilkimab 200 mg or placebo one time per week for 24 weeks in this double-blind, proof-of-concept, phase II study. The primary endpoint was change in modified Rodnan skin score (mRSS) from baseline to week 24. Results Ninety-seven patients were randomised to romilkimab (n=48) or placebo (n=49) for 24 weeks. Least-squares mean (SE) change in mRSS was –4.76 (0.86) for romilkimab versus –2.45 (0.85) for placebo yielding a mean (SE) (90% CI) difference of –2.31 (1.21) (–4.32 to –0.31; p=0.0291, one-sided). Treatment-emergent AEs were balanced between placebo (n=41; 84%) and romilkimab (n=40; 80%). Most were mild-to-moderate and discontinuations were low (three overall). There were two deaths (one scleroderma renal crisis (romilkimab) and one cardiomyopathy (placebo)), neither were considered treatment related. Two patients in the placebo group had a cardiovascular treatment-emergent SAE (one cardiac failure, one cardiomyopathy), but there were no cardiac safety signals with romilkimab. Conclusion This study demonstrated significant effects on skin changes with romilkimab in early dcSSc that require confirmation with a longer and more comprehensive phase III study to determine clinical relevance. Trial registration number NCT02921971 .
160O Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC)
Authors: A. Schneeweiss, V. Möbus, H. Tesch, P. Klare, C. Denkert, K. Kast, C. Hanusch, T. Link, M. Untch, C. Jackisch, J-U. Blohmer, P.A. Fasching, C. Solbach, J. Huober, K.E. Rhiem, V. Nekljudova, K. Lübbe, S. Loibl
Journal: Annals of Oncology (2020)
1546P Prognostic role of tumoral DNA damage repair protein expression in patients with resectable pancreatic cancer
Authors: F. Ceylan, D.C. Guven, H. Taban, O. Aktepe, S. Kilickap, A. Turker, E. Hamaloglu, D. Karakoç, A. Işık, A. Akyol, Ş. Yalçın, O. Dizdar
Journal: Annals of Oncology (2020)
614MO Cabazitaxel (CBZ) activity in men with metastatic castration resistant prostate cancer (mCRPC) with and without DNA damage repair (DDR) defects
Authors: M. Aldea, L. Lam, C. Llacer Perez, M. Saint-Ghislain, G. Gravis Mescam, A. Fléchon, G. Roubaud, P. Barthélémy, F. Ricci, F. Priou, Z.M. Neviere, M. Beaufils, C. Helissey, R. Ratta, C. Pobel, E. Castro Marcos, A. Thiery-Vuillemin, G. Baciarello, E. Orillard, K. Fizazi
Journal: Annals of Oncology (2020)
272TiP Dual-layer spectral detector CT: Clinical performance in patients with locally advanced breast cancer treated neoadjuvant with aromatase inhibitors
Authors: J. Reis, C.H. Kristiansen, J. Boavida, J.C. Lindstrøm, T. Sauer, J. Geisler, J.T. Geitung
Journal: Annals of Oncology (2020)
Characterizing Disease Features and Other Medical Diagnoses in Patients With Pityriasis Rubra Pilaris
Authors: Katherine Halper, Benjamin Wright, Nolan J. Maloney, Mindy M. Kim, Vignesh Ravi, Scott Worswick, Donald K. Lei
Journal: JAMA Dermatology (2020)

Characterizing Disease Features and Other Medical Diagnoses in Patients With Pityriasis Rubra PilarisPityriasis rubra pilaris (PRP) is a rare papulosquamous disorder that normally manifests with hyperkeratotic follicularbased papules, scaling erythematous plaques with areas of sparing, and palmoplantar keratoderma. 1 Considerable heterogeneity exists in the clinical features of PRP.Not all patients experience progression to erythroderma, and PRP is sometimes associated with a seronegative arthritis. 1,2 The prevalence of arthropathy in PRP or frequency of other known disease features such as alopecia or anhidrosis is unknown. 3,4 In addition, the prevalence of other medical diagnoses in patients with PRP is incompletely described.
763P The influence of multidisciplinary team meetings on treatment decisions in muscle invasive bladder cancer: A nationwide study in the Netherlands
Authors: J.E.W. Walraven, T.M. Ripping, J.R. Oddens, B.W.G. van Rhijn, C.A. Goossens-Laan, M.C.C.M. Hulshof, S.G. BlaZIB, L.A. Kiemeney, J.A. Witjes, K.K.H. Aben, V.E.P.P. Lemmens, J.J.M. van der Hoeven, I.M.E. Desar, R.H.A. Verhoeven
Journal: Annals of Oncology (2020)
1762P Delivery of systemic anti-cancer therapy during the COVID-19 pandemic
Authors: O. Fitzpatrick, R. Ní Dhonaill, A. Linehan, Z. Coyne, M. Hennessy, M. Clarke, E. McGee, F. Barrett, C. Matassa, D. O'Doherty, T. Doyle, A. Christie, B.T. Hennessy, L. Grogan, P.G. Morris, O.S. Breathnach, D. Cowzer
Journal: Annals of Oncology (2020)
Machine learning and atherosclerotic cardiovascular disease risk prediction in a multi-ethnic population
Authors: Andrew Ward, Ashish Sarraju, Sukyung Chung, Jiang Li, Robert Harrington, Paul Heidenreich, Latha Palaniappan, David Scheinker, Fatima Rodriguez
Journal: npj Digital Medicine (2020)

The pooled cohort equations (PCE) predict atherosclerotic cardiovascular disease (ASCVD) risk in patients with characteristics within prespecified ranges and has uncertain performance among Asians or Hispanics. It is unknown if machine learning (ML) models can improve ASCVD risk prediction across broader diverse, real-world populations. We developed ML models for ASCVD risk prediction for multi-ethnic patients using an electronic health record (EHR) database from Northern California. Our cohort included patients aged 18 years or older with no prior CVD and not on statins at baseline (n = 262,923), stratified by PCE-eligible (n = 131,721) or PCE-ineligible patients based on missing or out-of-range variables. We trained ML models [logistic regression with L2 penalty and L1 lasso penalty, random forest, gradient boosting machine (GBM), extreme gradient boosting] and determined 5-year ASCVD risk prediction, including with and without incorporation of additional EHR variables, and in Asian and Hispanic subgroups. A total of 4309 patients had ASCVD events, with 2077 in PCE-ineligible patients. GBM performance in the full cohort, including PCE-ineligible patients (area under receiver-operating characteristic curve (AUC) 0.835, 95% confidence interval (CI): 0.825-0.846), was significantly better than that of the PCE in the PCE-eligible cohort (AUC 0.775, 95% CI: 0.755-0.794). Among patients aged 40-79, GBM performed similarly before (AUC 0.784, 95% CI: 0.759-0.808) and after (AUC 0.790, 95% CI: 0.765-0.814) incorporating additional EHR data. Overall, ML models achieved comparable or improved performance compared to the PCE while allowing risk discrimination in a larger group of patients including PCE-ineligible patients. EHR-trained ML models may help bridge important gaps in ASCVD risk prediction.
1701P Oncological patients’ perception of infection risks and level of acceptance of protective measures during SARS-CoV-2 pandemic
Authors: D. Tregnago, S. Zuliani, I. Zampiva, M. Casali, A. Cavaliere, A. Fumagalli, S. Merler, S.T. Riva, A. Rossi, F. Zacchi, E. Zaninotto, A. Caldart, S. Casalino, M. Gaule, D. Kadrija, M. Mongillo, M. Rimondini, L. Del Piccolo, M. Milella, S. Pilotto
Journal: Annals of Oncology (2020)
Ureteral Stent Microbiota Is Associated with Patient Comorbidities but Not Antibiotic Exposure
Authors: Kait F. Al, John D. Denstedt, Brendan A. Daisley, Jennifer Bjazevic, Blayne K. Welk, Stephen E. Pautler, Gregory B. Gloor, Gregor Reid, Hassan Razvi, Jeremy P. Burton
Journal: Cell Reports Medicine (2020)

Ureteral stents are commonly used to prevent urinary obstruction but can become colonized by bacteria and encrusted, leading to clinical complications. Despite recent discovery and characterization of the healthy urinary microbiota, stent-associated bacteria and their impact on encrustation are largely underexplored. We profile the microbiota of patients with typical short-term stents, as well as over 30 atypical cases (all with paired mid-stream urine) from 241 patients. Indwelling time, age, and various patient comorbidities correlate with alterations to the stent microbiota composition, whereas antibiotic exposure, urinary tract infection (UTI), and stent placement method do not. The stent microbiota most likely originates from adhesion of resident urinary microbes but subsequently diverges to a distinct, reproducible population, thereby negating the urine as a biomarker for stent encrustation or microbiota. Urological practice should reconsider standalone prophylactic antibiotics in favor of tailored therapies based on patient comorbidities in efforts to minimize bacterial burden, encrustation, and complications of ureteral stents.
436P Phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second line treatment of KRAS-mutated metastatic colorectal cancer
Authors: D.H. Ahn, M. Erlander, M. Ridinger, E. Samuëlsz, A. Barzi, T. Bekaii-Saab, H.J. Lenz
Journal: Annals of Oncology (2020)
781P Prognostic factors in patients with metastatic urothelial carcinoma who have been treated with atezolizumab
Authors: D. Tural, Ö.F. Ölmez, A.T. Sümbül, N. Özhan, E. Akar, B. Çakar, O. Köstek, M. Ekenel, M. Erman, H.Ş. Çoşkun, F. Selçukbiricik, O. Keskin, F. Paksoy, K. Oruç, None S. Bayram, U. Yılmaz, I. Bilgetekin, B. Yıldız, M.A.N. Şendur, M. Artac
Journal: Annals of Oncology (2020)
698O Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) + platinum-based chemotherapy (PBC) vs placebo (PBO) + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)
Authors: A. Bamias, M. De Santis, J.Á. Arranz, E. Grande, M.D. Galsky, E. Kikuchi, S.H. Park, U. De Giorgi, X. Garcia del Muro, M. Mencinger, B. Alekseev, J. Puente, K. Izumi, M. Gumus, B. Mellado Gonzalez, J-R. Li, C. Quach, B. Ding, S. Bernhard, I.D. Davis
Journal: Annals of Oncology (2020)
396O Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study
Authors: T. André, M. Amonkar, J. Norquist, K-K. Shiu, T.W. Kim, B.V. Jensen, L.H. Jensen, C.J. Punt, D. Smith, R. Garcia-Carbonero, I. Sevilla, C. de la Fouchardiere, F. Rivera, E. Elez, L.A. Diaz, T. Yoshino, E. Van Cutsem, P. Yang, M.Z.H. Farooqui, D. Le
Journal: Annals of Oncology (2020)
523TiP MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer
Authors: J. Strickler, K. Ng, A. Cercek, C. Fountzilas, F. Sanchez, J. Hubbard, C. Wu, M. Stecher, L.N. Walker, T. Bekaii-Saab
Journal: Annals of Oncology (2020)
Splenectomy Is a Risk Factor for Cardiac Complications in TM
Authors: Antonella Meloni, Laura Pistoia, Angela Ciancio, Vincenzo Santamaria, Francesco Sorrentino, Carla Cirotto, Alessandra Quota, Nicola Romano, Aurelio Maggio, Riccardo Righi, Nicolò Schicchi, Alessia Pepe
Journal: Blood (2017)
363O Clinical characterization of a real-life cohort of 6001 patients with brain metastases from solid cancers treated between 1986-2020
Authors: A. Steindl, J. Kreminger, E. Moor, A. Starzer, K. Dieckmann, B. Gatterbauer, G. Widhalm, M. Preusser, A.S. Berghoff
Journal: Annals of Oncology (2020)
1324P Pembrolizumab as a monotherapy (P) or in combination with platinum-based chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) with PD-L1 tumour proportion score (TPS) ≥50%: A real-world data (Israeli Lung Cancer Group)
Authors: E. Dudnik, M. Moskovitz, Y. Rottenberg, A. Lobachov, R. Mandelboim, T. Shochat, D. Urban, M. Wollner, H. Nechushtan, O. Rotem, A. Zer, J. Bar
Journal: Annals of Oncology (2020)
1578P COVID-19 and hospitalised cancer patients: Now it’s time for patients to talk
Authors: B. Domingo Arrue, R.M. Pastor Marí, A. Tarazona Ortega, L. Fos Saus, C.A. Puchades Olmos, A. Torres Martinez, D. Soriano Polo, G. Suay Montagud, A. Ferrero Micó, F.J. Perea Rojo, N. Gómez Sepúlveda, J.D. Linares Diaz, R.P. Diaz Beveridge, R. Girones Sarrio
Journal: Annals of Oncology (2020)
1466P Clinical implications of neutrophil-to-lymphocyte ratio and MDSC kinetics in gastric cancer patients treated with ramucirumab plus paclitaxel
Authors: H-D. Kim, M.H. Ryu, S. Yoon, Y-S. Na, M. Moon, H. Lee, H.G. Song, Y-K. Kang
Journal: Annals of Oncology (2020)
1643P Demographics and outcomes of non-metastatic Ewing’s sarcoma (ES) from a low-middle income country (LMIC)
Authors: G.S. Panda, J. Bajpai, S. Dandekar, S. Mokal, P. Bhargava, T. Vora, J. Ghosh, B. Rekhi, K. Prabhash, S. Banavali, S. Gupta
Journal: Annals of Oncology (2020)
1939P Potential role of longitudinal plasma next generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) experiencing hyperprogression (HPD) and early death (ED) during treatment with immune checkpoint inhibitors (ICIs)
Authors: L. Bonanno, E. Zulato, I. Attili, G. Nardo, A. Pavan, D.B. Paola, A. Boscolo Bragadin, G. Pasello, V. Guarneri, P.F. Conte, S. Indraccolo
Journal: Annals of Oncology (2020)
1660P The promising role of the extracellular matrix in the activity of trabectedin in soft tissue sarcoma: A prospective study on a UPS and L-sarcoma patient-derived primary culture case series using 3D and zebrafish models
Authors: A. De Vita, F. Recine, G. Miserocchi, F. Pieri, C. Spadazzi, C. Cocchi, C. Liverani, A. Farnedi, F. Fabbri, V. Fausti, R. Casadei, F. Brandolini, G. Ercolani, D. Cavaliere, A. Bongiovanni, N. Riva, L. Gurrieri, S.A. Debonis, L. Mercatali, T. Ibrahim
Journal: Annals of Oncology (2020)
1917P Pembrolizumab salvage add-on therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC) progressing on lenvatinib: Results of a multicenter phase II International Thyroid Oncology Group Trial
Authors: B. Haugen, J.D. French, F. Worden, B. Konda, E.J. Sherman, R. Dadu, A.G. Gianoukakis, S. Mccue, N. Foster, D.W. Bowles, L.J. Wirth
Journal: Annals of Oncology (2020)
1423MO End-of-study analysis from JACOB: A phase III study of pertuzumab (P) + trastuzumab (H) and chemotherapy (CT) in HER2-positive metastatic gastric or gastro-esophageal junction cancer (mGC/GEJC)
Authors: J. Tabernero, P.M. Hoff, L. Shen, A. Ohtsu, M.A. Shah, A. Siddiqui, S. Heeson, H. Wu, E. Restuccia, Y-K. Kang
Journal: Annals of Oncology (2020)
1476P NUTRitional Index for immune-checkpoint inhibitors (ICI) (NUTRICI) for patients (pts) with metastatic gastro-oesophageal junction (GOJ)/gastric cancer (GC)
Authors: C. Morelli, V. Formica, A. Patrikidou, C. Murias, S-U-R. Butt, J. Lucchetti, N. Renzi, D. Nitti, K-K. Shiu, M. Roselli, T. Arkenau
Journal: Annals of Oncology (2020)
1679P Determinants of mortality from SARS-CoV-2 infection in European cancer patients
Authors: D.J. Pinato, C. Sng, Y.N.S. Wong, F. Biello, E. Seguí, J. Aguilar-Company, A. Carbo Bague, A. Patriarca, M.D. Bower, G. Rizzo, R. Bruna, C.A. Cruz, F. D'Avanzo, T. Newsom-Davis, M. Mollà, G. Gaidano, J. Brunet, J. Tabernero, A. Prat, A. Gennari
Journal: Annals of Oncology (2020)
1147P Primary ipilimumab/nivolumab immunotherapy followed by adjuvant nivolumab in locally advanced or oligometastatic melanoma: Preliminary results
Authors: E. Cocorocchio, L. Pala, L. Nezi, T. Manzo, L. Mazzarella, L. Fiorenza, S. Gandini, F. Conforti, G. Mazzarol, P. Queirolo, E. Pennacchioli, G.M. Orsolini, M.T. Fierro, S. Ribero, R. Senetta, P. Fava, F. Picciotto, V. Caliendo, P. Quaglino, P.F. Ferrucci
Journal: Annals of Oncology (2020)
1339P Clinicopathological characteristics and treatment patterns observed in real-world care in patients with advanced non-small cell lung cancer (NSCLC) and KRAS G12C mutations in the Flatiron Health (FH)-Foundation Medicine (FMI) Clinico-Genomic Database (CGDB)
Authors: S. Aggarwal, S. Whipple, H. Hsu, H. Tu, G. Carrigan, X. Wang, G. Ngarmchamnanrith, V. Chia
Journal: Annals of Oncology (2020)
Water-irrigation disimpaction endoscopic retrograde cholangiopancreatography – an approach to impacted distal biliary stones
Authors: Chieh Sian Koo, Bhavesh Kishor Doshi, Calvin Jianyi Koh
Journal: Endoscopy (2020)

Distal common bile duct impaction is common during management of large choledocholithiasis. Despite lithotripsy, impaction of the stone fragments, ampullary edema, and the presence of a periampullary diverticulum can limit balloon extraction [1]. We present a case where water irrigation of the common bile duct proved to be a useful adjunct in the atraumatic removal of impacted distal biliary stone fragments, allowing for successful completion of the procedure ([Video 1]).
Transplanted microvessels improve pluripotent stem cell–derived cardiomyocyte engraftment and cardiac function after infarction in rats
Authors: Xuetao Sun, Jun Wu, Beiping Qiang, Rocco Romagnuolo, Mark Gagliardi, Gordon Keller, Michael A. Laflamme, Ren-ke Li, Sara S. Nunes
Journal: Science Translational Medicine (2020)

Microvessels enhance survival of hiPSC-derived cardiomyocytes, improving remuscularization and cardiac function after myocardial infarction in rats.
449P Randomized phase II study comparing pathological responses of resected colorectal cancer metastases (CRCM) after bevacizumab (BEV) with FOLFOX or FOLFIRI (BEV-ONCO trial)
Authors: P. Baldin, G. Beniuga, A. Jouret-Mourin, G. Demolin, S. Roland, L.A. D'Hondt, P. Vergauwe, D. Vandaele, M. Mailleux, I. Sinapi, A. De Cuyper, N. Bletard, B. Massart, M. Delos, M-L. Castella, A. van Maanen, J. Carrasco, M. van den Eynde
Journal: Annals of Oncology (2020)
1881P Deterioration of sexual health of cancer survivors 5 years after diagnosis – French national cohort VICAN
Authors: L. Seguin, R. Touzani, A-D. Bouhnik, A. Ben CharifF, P. Marino, M.K. Bendiane, A. Gonçalves, G. Gravis Mescam, J. Mancini
Journal: Annals of Oncology (2020)